REal-world Data of CARdiometabolic ProtEcTion

Recruiting now

Conditions studied: Cardiometabolic Diseases

In brief

This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. The primary outcome of the study is all-cause death and cardiovascular death, and the secondary outcome is major adverse cardiovascular events. We aim to measure associations of established or suspected cardiometabolic disease (CMD) risk factors and cardiovascular disease outcomes in a real-world representative cohort.

Key facts

Study ID

NCT07038083

Run by

Sun Yat-sen University

People needed

40000

Starts

2014-01-01

Expected to finish

2044-01-01

Last updated by the study team

2025-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients over 18 years old;
• Patients with clinical diagnosis of metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia.
• Hypertension and normal high blood pressure: Three standardized blood pressure measurements in the clinic on different days, and all the blood pressure values of the three measurements were systolic blood pressure ≥ 120 mmHg and/or diastolic blood pressure ≥ 80 mmHg;
• Diabetes: ① Typical symptoms of diabetes, and any of the following: ② Random blood glucose ≥ 11.1 mmol/L; ③ Fasting blood glucose (FPG) ≥ 7.0 mmol/L; ④ OGTT 2-hour postprandial blood glucose ≥ 11.1 mmol/L; ⑤ HbA1c ≥ 6.5%;
• Obesity and overweight: Body mass index (BMI) ≥ 24 kg/m²;
• Dyslipidemia: At least one of the following lipid indicators is abnormal: ① Total cholesterol (TC) ≥ 6.2 mmol/L; ② Low-density lipoprotein cholesterol (LDL-C) ≥ 4.1 mmol/L; ③ High-density lipoprotein cholesterol (HDL-C) < 1.0 mmol/L; ④ Triglyceride (TG) ≥ 2.3 mmol/L; ⑤ Lipoprotein(a) ≥ 30 mg/dL;
• Hyperuricemia: The fasting blood uric acid levels on two different days were > 420 μmol/L (7 mg/dL) in men and > 360 μmol/L (6 mg/dL) in women.

You may not qualify if…

• Patients unable to provide informed consent.

Where it is running

• The First Affiliated Hospital of Sun Yat-sen Univerity — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.